✦ LIBER ✦

162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia

✍ Scribed by H.D. Preisler; X-K. Huang; A. Raza

Book ID: 114119351
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 143 KB
Volume: 21
Category: Article
ISSN: 0145-2126
DOI: 10.1016/s0145-2126(97)81372-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Some reasons for the lack of progress in

Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients

✍ Harvey Preisler; Azra Raza; Richard Larson; Jack Goldberg; Guido Tricot; Mark Ca 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 749 KB

Thrombopoietic factors potentially usefu

Thrombopoietic factors potentially useful in the treatment of acute leukemia

✍ Eric Archimbaud; Xavier Thomas 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 102 KB

New Strategies for the Treatment of Acut

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

✍ Øystein Bruserud; Bjørn Tore Gjertsen 📂 Article 📅 2000 🏛 AlphaMed Press 🌐 English ⚖ 56 KB

Generation of functional dendritic cells

Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia

✍ Dagmar Pospíšilová, Jiřina Borovičková, Andrea Poloučková, Radek Špíšek, Anna Še 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 209 KB

Report and recommendations of the rome w

Report and recommendations of the rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment

✍ Mastrangelo, R. ;Poplack, D. ;Bleyer, A. ;Riccardi, R. ;Sather, H. ;D'Angio, G. 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

Chronic myelogenous leukemia in nonlymph

Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was